entertainment -WSS

entertainment

author：knowledge 2025-09-27 12:57:42 - browse：6819

Courtesy Guardant Health

An independent panel of advisers to the Food and Drug Administration recommended the agency approve Guardant Health’s blood-based colon cancer detection test. If the agency follows the recommendation, it will clear an early hurdle for the test’s broader adoption.

The expert panel spent hours listening to presentations from Guardant, the FDA, and members of the public before voting on the screening test, called Shield. The panel’s nine voting members then voted on whether the test was safe, effective, and whether its benefits outweigh its risks, with eight, six, and seven panelists endorsing those views, respectively.

FDA approval is a requirement for winning coverage from the Centers for Medicare and Medicaid Services, which could be the difference between Guardant’s test becoming widespread — or irrelevant. In 2021, CMS denied coverage for Epi proColon, a different blood-based colon cancer test approved by the FDA. Soon after, the test’s maker, Epigenomics, announced that it would stop actively marketing the test, and last year the company announced a restructuring that included layoffs.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Medicare proposal to cover medical devices draws a mixed reaction
Next article： Novo Nordisk obesity pill bests Wegovy in early trial

focus

WSS

CDC marks new Covid

JPM 2024: Biotech’s most prolific dealmaker sees a rosy 2024

Nonprofit, backed by Microsoft, to certify AI tools in health care

JPM pitch from hospitals? Revenue streams outside of patient care

Precocious puberty in girls comes with mental health risks

Gene therapy denied for Afghan refugee whose father aided U.S.

knowledge

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Wikipedia

Walensky prepares to leave CDC — and Congress — behind

Amylyx ALS drug failure raises questions and concerns

23andMe had bad news about my health. I wish a person had delivered it

Change Healthcare cyberattack prompts Medicare loan program

Virginia high school admissions case could be legal follow

UnitedHealth quietly bought dozens of outpatient centers

The cancer drug shortage isn’t new — and neither are the solutions

CDC marks new Covid

Apple is now the first public company to be valued at $3 trillion

Novo Nordisk obesity pill bests Wegovy in early trial

leisure time

A preacher's new calling: Diversifying neuroscience research

Novo Nordisk obesity pill bests Wegovy in early trial

Gene therapy denied for Afghan refugee whose father aided U.S.

Profiling embryos to choose those with higher IQs is almost a reality

FDA early review: GLP

IVF, abortion rights issues kick off Biden’s State of the Union

knowledge

leisure time

focus

focus